Active — Not RecruitingNot Applicable

Molecular Evaluation of AML Patients After Stem Cell Transplant to Understand Relapse Events

United States303 participantsStarted 2022-08-26

Plain-language summary

Prospective determination of the clinical utility of measurable residual disease (MRD) testing for relapse and survival of patients with acute myeloid leukemia (AML) undergoing allogeneic hematopoietic cell transplantation (alloHCT).

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Provision of signed and dated informed consent form
✓. Stated willingness to comply with all study procedures and availability for the duration of the study
✓. Aged at least 18 years old at time of consent
✓. Diagnosed with AML, in complete remission
✓. Complete remission (CR) definition per local institutional criteria

Exclusion criteria

✕. MRD positivity is not an exclusion criterion
✕. Undergoing alloHCT
✕. Has a diagnostic AML specimen available
✕. Diagnosis of acute promyelocytic leukemia
✕. Prior alloHCT

What they're measuring

Overall Survival

Timeframe: Through up to 3 years post-alloHCT

Cumulative incidence of relapse

Timeframe: Through up to 3 years post-alloHCT

Trial details

NCT IDNCT05224661

SponsorCenter for International Blood and Marrow Transplant Research

Sponsor typeNETWORK

Study typeOBSERVATIONAL

Primary completion2029-07-01

View on ClinicalTrials.gov More Acute Myeloid Leukemia in Remission trials